Dr Gomez Arteaga on an Investigation of Orca-T Vs PTCy-Based HCT in Acute Leukemia and MDS
Alexandra Gomez Arteaga, MD, discusses a retrospective study of Orca-T vs post-transplant cyclophosphamide in acute leukemia and MDS.
Source: onclive.com
Page 12 - Cellular Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cellular Therapy Today - Breaking & Trending Today
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.
Source: onclive.com
ASTCT to Present Distinguished Honors at the 2024 Tandem Meetings
CHICAGO, IL / ACCESSWIRE / February 22, 2024 / American Society for Transplantation and Cellular Therapy® (ASTCT) presents top awards to leaders in the field of transplantation and cellular therapy at the Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®, Feb. 21-24 in San Anton...
Source: pharmiweb.com
Acalabrutinib/Axi-Cel Generates Preliminary Responses in Relapsed/Refractory B-Cell Lymphoma
Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.
Source: onclive.com
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in
Source: eagletribune.com